Literature DB >> 28401127

Diagnostic and referral intervals for Manitoba women with epithelial ovarian cancer - the Manitoba Ovarian Cancer Outcomes (MOCO) study group: a retrospective cross-sectional study.

Allison J Love1, Pascal Lambert1, Donna Turner1, Robert Lotocki1, Erin Dean1, Shaundra Popowich1, Alon D Altman1, Mark W Nachtigal1.   

Abstract

BACKGROUND: Epithelial ovarian cancer has the highest mortality of all gynecologic cancers. The poor survival rates are often attributed to the advanced stage at which most of these cancers are detected. We sought to examine the effects of patient demographics, comorbidities and presenting symptoms on diagnostic and referral intervals by location of first presentation (emergency department v. elsewhere) and to identify factors that affect these intervals.
METHODS: We performed a retrospective analysis of chart and medical record data for ovarian cancers, with the exceptions of sex cord and germ cell tumours, diagnosed between 2004 and 2010 in Manitoba, Canada. Data were collected on baseline characteristics, time to diagnosis and referral, number and type of physician visits and emergency department visits.
RESULTS: The final cohort consisted of 601 patients. Sixty-three percent of patients received their diagnosis within 60 days of initial presentation, and 75.2% had their cancer diagnosed within 2 physician encounters. The median diagnostic interval for all stages of patients presenting to the emergency department was 7 days, compared with 55 days for patients presenting elsewhere. Early stage patients not presenting to the emergency department had their diagnosis a median of 34.0 days later than patients with advanced disease (95% confidence interval [CI] 22.22 to 45.69, p < 0.0001). The presence of some symptoms was associated with shortened diagnostic intervals. Patients with serous, clear-cell or endometrioid histotypes were less likely to have first presentation beginning in the emergency department (odds ratio [OR] 0.40, 95% CI 0.24 to 0.64, p = 0.0001; OR 0.28, 95% CI 0.14 to 0.59, p = 0.007) than those with unclassified epithelial histotype.
INTERPRETATION: For this group of patients, the main factor associated with diagnostic and referral intervals is presentation to the emergency department. These patients likely required more urgent attention for their more symptomatic disease, leading to quicker diagnosis and referral patterns, despite poorer prognosis.

Entities:  

Year:  2017        PMID: 28401127      PMCID: PMC5378539          DOI: 10.9778/cmajo.20160100

Source DB:  PubMed          Journal:  CMAJ Open        ISSN: 2291-0026


  20 in total

1.  Symptom presentation in invasive ovarian carcinoma by tumor histological type and grade in a multiethnic population: a case analysis.

Authors:  Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Rayna K Matsuno; Michael E Carney; Marc T Goodman
Journal:  Gynecol Oncol       Date:  2010-06-29       Impact factor: 5.482

2.  Delay in diagnosis of epithelial ovarian cancer.

Authors:  C Wikborn; F Pettersson; P J Moberg
Journal:  Int J Gynaecol Obstet       Date:  1996-03       Impact factor: 3.561

3.  Quantifying treatment delays in adolescents and young adults with cancer at McGill University.

Authors:  Y Xu; M Stavrides-Eid; A Baig; M Cardoso; Y S Rho; W M Shams; A Mamo; P Kavan
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

4.  Effect of delays in primary care referral on survival of women with epithelial ovarian cancer: retrospective audit.

Authors:  John M J Kirwan; Douglas G Tincello; Jonathan J O Herod; Olive Frost; Robert E Kingston
Journal:  BMJ       Date:  2002-01-19

5.  Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Authors:  Christina M Nagle; Jane E Francis; Anne E Nelson; Helen Zorbas; Karen Luxford; Anna de Fazio; Sian Fereday; David D Bowtell; Adèle C Green; Penelope M Webb
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

6.  Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.

Authors:  Lucy Gilbert; Olga Basso; John Sampalis; Igor Karp; Claudia Martins; Jing Feng; Sabrina Piedimonte; Louise Quintal; Agnihotram V Ramanakumar; Janet Takefman; Maria S Grigorie; Giovanni Artho; Srinivasan Krishnamurthy
Journal:  Lancet Oncol       Date:  2012-01-17       Impact factor: 41.316

7.  Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership.

Authors:  Camille Maringe; Sarah Walters; John Butler; Michel P Coleman; Neville Hacker; Louise Hanna; Berit J Mosgaard; Andy Nordin; Barry Rosen; Gerda Engholm; Marianne L Gjerstorff; Juanita Hatcher; Tom B Johannesen; Colleen E McGahan; David Meechan; Richard Middleton; Elizabeth Tracey; Donna Turner; Michael A Richards; Bernard Rachet
Journal:  Gynecol Oncol       Date:  2012-06-27       Impact factor: 5.482

8.  The effect of symptom duration in epithelial ovarian cancer on prognostic factors.

Authors:  Joseph Menczer; Angela Chetrit; Siegal Sadetzki
Journal:  Arch Gynecol Obstet       Date:  2008-10-21       Impact factor: 2.344

9.  Delays in the diagnosis of six cancers: analysis of data from the National Survey of NHS Patients: Cancer.

Authors:  V L Allgar; R D Neal
Journal:  Br J Cancer       Date:  2005-06-06       Impact factor: 7.640

10.  Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records.

Authors:  Aww Lim; D Mesher; A Gentry-Maharaj; N Balogun; M Widschwendter; I Jacobs; P Sasieni; U Menon
Journal:  BJOG       Date:  2015-05-29       Impact factor: 6.531

View more
  2 in total

1.  Mode of Referral of Ovarian Cancer Patients: Does it Alter Treatment and Survival?

Authors:  Anas Barakat; Aemn Ismail; Quentin Davies; Supratik Chattopadhyay
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

2.  Real-World Treatment Patterns, Survival, and Costs for Ovarian Cancer in Canada: A Retrospective Cohort Study Using Provincial Administrative Data.

Authors:  Manjusha Hurry; Shazia Hassan; Soo Jin Seung; Ryan N Walton; Ashlie Elnoursi; Jacob D McGee
Journal:  J Health Econ Outcomes Res       Date:  2021-12-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.